TP53 glioma GWAS variants c.*1175A>C8,20, which has been identified to account for ∼6% of the familial risk of glioma20, and its lead SNP c.376-117G>A21 (variant frequency 0.02 and 0.03 in the Finnish population, respectively), were identified in Family P in the two affected siblings having oligodendroglioma grade II and ganglioglioma grade I within the ages of 10–14 and 30–34 years, respectively (Supplementary Table 5). The gene discussed is TP53; the disease is central nervous system cancer.